About Us
Nebulabio is a specialized mammalian cell line engineering team dedicated to developing high-performance stable production cell lines for biosimilar and biobetter therapeutics. By integrating reference product analytical deconstruction, optimized expression cassette design, productivity-driven clone screening, and structured comparability assessment, we generate clonal production cell lines aligned with defined target product quality profiles. Our service supports the full biosimilar development continuum—from reference product characterization and construct engineering to stable cell line generation, analytical similarity documentation, and bankable clone delivery.
☞Our Biosimilar Cell Line Development Platform
Biosimilar development requires alignment of productivity with rigorous analytical and functional similarity to the reference product. Our platform combines reverse engineering of innovator molecules, QbD-guided vector architecture, high-throughput clone screening that integrates titer with critical quality attribute assessment, and extended stability evaluation under non-selective conditions. The result is a traceable, stable production clone supported by structured comparability data across physicochemical and biofunctional parameters.
☞Supported Options
Host Cell Lines
| Expression Vector Systems
| |
Transfection and Stable Pool Generation
| Single-Cell Cloning and Screening
|
☞Principle of Biosimilar Cell Line Development
Biosimilar cell line development begins with defining a multidimensional target product quality profile derived from comprehensive analytical characterization of the reference molecule. The expression construct encodes an identical amino acid sequence while incorporating optimized regulatory elements to support stable, high-level expression in CHO hosts. Following transfection and selection, extensive clonal populations are screened not only for productivity but also for critical quality attributes including glycosylation pattern, charge heterogeneity, aggregate level, and functional bioactivity. Lead clones are subjected to extended culture without selection to confirm sustained productivity and consistent product quality. Comparative analytical assessment between biosimilar candidate material and the reference product provides the technical foundation for regulatory demonstration of biosimilarity.
| ☎ +86-15801534258 | ✉ info@nebulabio.cn | Request a Quote ☜ |
☞Nebulabio Service Workflow
Reference Product Analysis and Target Profile Definition We define quantitative similarity windows that guide clone selection and quality benchmarking. Key Steps
Construct Design and Vector Engineering We design an optimized expression cassette encoding the exact reference sequence for stable CHO expression. Key Steps
Transfection and Stable Pool Generation We establish productive stable pools under defined selection conditions with early productivity and quality checkpoints. Key Steps
Single-Cell Cloning and High-Throughput Screening We isolate monoclonal lines and rank clones based on integrated productivity and analytical similarity metrics. Key Steps
Lead Clone Characterization and Comparability Study We confirm stability and similarity under manufacturing-relevant conditions. Key Steps
Cell Banking and Documentation We generate bankable production clones with structured regulatory-ready documentation. Key Steps
|
☞Featured Applications
■ Monoclonal Antibody Biosimilars
Stable CHO production clones are developed to match glycan distribution, charge variants, aggregation levels, and Fc-mediated functional profiles of reference monoclonal antibodies. Integrated clone ranking reduces late-stage comparability risk by identifying candidates with aligned CQAs early in development.
■ Fc-Fusion Protein Biosimilars
Fc-fusion biologics require controlled disulfide pairing and glycosylation alignment to maintain structural integrity and bioactivity.
■ Peptide Hormone and Protein Biosimilars
CHO-derived stable lines expressing recombinant peptide hormones or therapeutic proteins enable controlled processing and consistent quality for analytical comparability programs.
■ Biobetter Development Programs
Beyond strict biosimilarity, the same structured workflow supports rational sequence modifications intended to improve manufacturability or pharmacological properties while maintaining substantial structural similarity for streamlined development strategies.
| For more information, please contact us at info@nebulabio.cn or +86-15801534258. |
